Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00533091 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis

A Phase 1 study, sponsored by MedImmune.

Completed
Registry status
Phase 1
Development phase
51
Enrollment target

NCT00533091: Completed Phase 1 study, sponsored by MedImmune.

NCT00533091 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 51 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00533091, a Phase 1 study, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 1
Development phase
51 participants
Enrollment target

Study Summary

The primary objective of the study is to evaluate the safety and tolerability of multiple IV doses of MEDI-545 in adult patients with myositis.

Interventions

  • OTHER Placebo
  • BIOLOGICAL MEDI-545

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2008-04
Est. Completion 2010-10
Phase Phase 1
MedImmune

210 total trials

What the finished NCT00533091 record still lists

NCT00533091 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00533091 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00533091 about?

NCT00533091 is a clinical study titled "A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis". The primary objective of the study is to evaluate the safety and tolerability of multiple IV doses of MEDI-545 in adult patients with myositis.

What is the current status of trial NCT00533091?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2008-04. Estimated completion is 2010-10.

What interventions are being tested in trial NCT00533091?

The interventions under investigation include: Placebo (OTHER), MEDI-545 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00533091?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00533091's enrollment target sits among peer trials

51 969th of 2000 higher than 1,028 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02701153 · 51 participants · NA

    Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

  • NCT03663790 · 51 participants · NA

    Effects of Gait Retraining on Lower Extremity Biomechanics

  • NCT03874052 · 51 participants · Phase 1

    Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • NCT04704661 · 51 participants · Phase 1

    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00533091, the US trial registry maintained by the National Library of Medicine. NCT00533091 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.